A Phase 1 Study to Evaluate IL13Rα2-Targeted Chimeric Antigen Receptor (CAR) T Cells for Adult Patients With Leptomeningeal Glioblastoma, Ependymoma or Medulloblastoma
Latest Information Update: 09 Jun 2025
At a glance
- Drugs MB 101 (Primary)
- Indications Ependymoma; Glioblastoma; Medulloblastoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 03 Jun 2025 Status changed from recruiting to active, no longer recruiting.
- 09 Mar 2022 Planned End Date changed from 15 Dec 2023 to 17 Nov 2025.
- 09 Mar 2022 Planned primary completion date changed from 15 Dec 2023 to 17 Nov 2025.